Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.

User makes topical finasteride with stemoxydine and proscar pills, stores at room temperature. Asks if solution goes bad in 3 months.

Kx-826 at 0.5% shows limited effectiveness for hair loss, while 1% is more promising but expensive. RU58841 is considered a more feasible option until 1% kx-826 becomes affordable.

The conversation discusses Kevin's accurate information on hair loss treatments and highlights Dr. Bloxham's ongoing work with Verteporfin on FUT scars, suggesting people follow Dr. Bloxham's YouTube for updates. It also thanks Haicafe and Melvin from the hair restoration network forum for their contributions.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

A user experienced no reduction in DHT levels after 8 months of finasteride, despite initial improvement in hair loss. They are considering switching to dutasteride but are concerned about potential side effects.

A poem humorously suggests hope for a new hair loss treatment, PP405, while users debate the effectiveness and side effects of current treatments like Finasteride. Concerns are raised about Finasteride's side effects, especially for young users, and skepticism about new treatments is expressed.

The conversation is about a product called FLEAVA, found in a Facebook ad, and whether it is effective or just another scam. One user believes it is likely a scam and mentions that such products usually don't compete with Minoxidil.

The user is experiencing a burning sensation on their scalp despite using finasteride and nizoral for hair loss, and is unsure if they should switch to dutasteride. They have reduced their testosterone dose but the burning persists, and a trichologist suggested it might be telogen effluvium.

The conversation discusses using very low dose topical finasteride to achieve specific serum DHT reduction percentages. It concludes that finasteride dosage increases linearly between 5-30% DHT reduction but requires exponential increases for reductions up to 70%.

Concerns about the long-term effects of dutasteride and finasteride on fertility, with discussions on cycling these medications to mitigate risks. The conversation highlights skepticism about study methodologies and the importance of weighing treatment risks against potential fertility issues.

People are not using RU58841 for hair loss because it's not FDA approved, lacks long-term safety data, and is difficult to obtain and verify. They prefer FDA-approved treatments like minoxidil, finasteride, ketoconazole shampoo, and microneedling.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

Researching the release of phase 2 trials for pyrilutamide, a potential hair loss treatment, and discussing other treatments such as Minoxidil, Finasteride, and RU58841.

A user experienced high estrogen levels after 10 months of taking 1mg oral finasteride but is happy with hair regrowth. They are considering switching to topical finasteride and are also taking DIM and Zinc supplements.

The user experienced a slight decrease in hair shedding and scalp itch, and reduced sebum production using Pyrilutamide, but stopped due to chest pain, breathing difficulties, and heart issues. They felt normal a week after discontinuing and doubted FDA approval for the drug.

RU58841 is discussed for hair loss treatment, with mixed reviews on its effectiveness and side effects. Users mention using it in an ethanol/PG solution and combining it with other treatments like dutasteride.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

The user stopped using finasteride due to side effects and switched to RU58841, which seems to be working for hair regrowth. They are considering RU58841 and minoxidil as long-term treatments, while others discuss the safety and effectiveness of these options.

Verteporfin is discussed as a potential treatment for scarring alopecia. Minoxidil is suggested as an alternative treatment.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

Hair loss discussion focused on Fluridil treatment. Availability of higher concentrations questioned.

The user is using a topical dutasteride/minoxidil/tretinoin gel for hair thinning and has had a positive experience with no side effects. They also mention considering another product, Formula82D, after having decent results with Formula82F.

The user has been using pyrilutamide, topical finasteride, and 15% minoxidil for hair growth for almost 4 years. Despite mixed responses from others, the user reports seeing progress, especially with the addition of pyrilutamide, and plans to continue the regimen.

User plans to use hair fibers regularly and asks about re-application, consistency, rain protection, and Boldify vs Toppik. Others provide advice and share experiences.

The conversation discusses using RU58841 or Pyrilutamide for hair loss, with some users suggesting switching to more proven treatments like oral or topical finasteride. One user reports no progress with RU58841, finasteride, and minoxidil, and mentions experiencing regression.

User switched from Fin to Dut for better hair loss results, using 0.5mg Dut and 1ml Min daily. Some discuss potential side effects and benefits of Dut compared to Fin.

PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.

Potential treatments for hair loss, specifically the combination of liquid minoxidil and pyrilutamide, with some suggesting that adding finasteride may be beneficial.

First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.